American Society of Hematology 2025
Preview oral and poster presentations shared by Dana-Farber physician-scientists at the 67th American Society of Hematology Annual Meeting & Exposition in Orlando, FL on Dec. 5-9th, 2025.
News Releases
- Dana-Farber–Led Studies in Sickle Cell Disease, Waldenström’s, Follicular and Mantle Cell Lymphomas, and MDS Presented at ASH 2025
- Childhood leukemia care puts one in three families at risk of poverty
- Phase III VERONA trial results show potential benefit for some groups with myelodysplastic syndrome (MDS)
- Triplet Therapy Shows Promise for BPDCN, a rare blood cancer, in Dana-Farber Study
- Chemo-free Regimens Show Promise, Could Redefine Care for B-Cell Lymphomas
- Dana-Farber Cancer Institute drives deep remissions in Waldenström’s with targeted, time-limited therapies
- Sickle-cell disease associated with early onset of clonal hematopoiesis, a precancerous condition
CME
-
Couldn't attend ASH? Save the date for Dana-Farber’s ASH Highlights CME on January 24, 2026.
Subscribe
-
Subscribe to “Advances in Hematologic Malignancies” to receive our bi-annual enewsletter with research and clinical updates, providing comprehensive information about our Division of Hematologic Malignancies
Follow us on social media
- X (formerly Twitter)
- @DanaFarber Cancer Institute - Information on our expert cancer care and advanced research
- @DanaFarberNews - Your source for Dana-Farber news
- Bluesky